Exact Therapeutics AS

ACT Technology Shows Promising Results in Enhancing Chemotherapy for Colorectal Liver Metastases

5 days ago

• EXACT Therapeutics' Phase 1 ACTIVATE trial demonstrates that Acoustic Cluster Therapy (ACT) significantly enhances chemotherapy effectiveness, with ACT-treated tumors showing 29% reduction in diameter compared to 7% with chemotherapy alone. • The innovative treatment demonstrated a clear dose-response relationship, with higher doses (40 μl/kg) of PS101 producing greater tumor shrinkage than lower doses (20 μl/kg), while maintaining an excellent safety profile. • These positive results support advancement to the Phase 2 ENACT trial targeting pancreatic cancer, potentially offering new hope for patients with difficult-to-treat solid tumors.